Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

Inflammatory Bowel Disease

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study

J Crohns Colitis

Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK

doi: 10.1093/ecco-jcc/jjaf213

Inflammatory Bowel Disease

Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial

Clin Gastroenterol Hepatol

Sands BE, Barnes EL, D'Haens G, Hisamatsu T, Regueiro M, Kelly CR, Laharie D, Hozak RR, Yu G, Gandhi R A, Lopes MU, Durand F, Protic M, Moses RE, Vermeire S

doi: 10.1016/j.cgh.2026.01.049

Inflammatory Bowel DiseaseFurther Publications

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study

Am J Gastroenterol

Lichtenstein GR, Allegretti JR, Rubin DT, Magro F, Bressler B, Panés J, Afif W, Samaan MA, Ye BD, Yarandi S, Germinaro M, Shipitofsky N, Miao Y, Zhang H, Dignass A, Sands BE, Hisamatsu T, Peyrin-Biroulet L

doi: 10.14309/ajg.0000000000004041

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

J Gastroenterol Hepatol

Wei SC, Nakase H, Ye BD, Chao K, Wu HY, Eccleston J, Yao X, Palac H, Mohamed MF, Ponce-Bobadilla AV, Suravaram S, Barrachina EM, Hisamatsu T, Gao X

doi: 10.1111/jgh.70634

Inflammatory Bowel Disease

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group

doi: 10.1016/S2468-1253(25)00322-X

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Inflamm Bowel Dis

Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkuś J, Kang B, Berezny K, Padgett L, Mao G, Zitser Y, Strauss RS, Verhoeven J, Adedokun OJ, Hyams JS

doi: 10.1093/ibd/izaf322

Inflammatory Bowel Disease

Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study

J Crohns Colitis

D'Amico F, Fanizzi F, Dal Buono A, Gabbiadini R, Nardone OM, Zilli A, Allocca M, Lauriola GM, Jairath V, Peyrin-Biroulet L, Fiorino G, Castiglione F, Massimino L, Mastronardi M, Armuzzi A, Danese S

doi: 10.1093/ecco-jcc/jjag062

Inflammatory Bowel Disease

Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID

United European Gastroenterol J

Calméjane L, Reenaers C, Gay C, Amiot A, Nuzzo A, Vuitton L, Atanasiu C, Stefanescu C, Altwegg R, Guillo L, Serrero M, Bouguen G, Nachury M, Cosquer GL, Roblin X, Abitbol V, Hammoudi N, Simon M, Fumery M, Savoye G, Benezech A, Cavicchi M, Charkaoui M, Buisson A, Caron B, Coffin B, Geyl S, Goutorbe F, Hupé M, Vidon M, Laharie D, Kirchgesner J, Uzzan M, GETAID‐AFTER‐VEDO Study Group

doi: 10.1002/ueg2.70203

Gastrointestinal Cancer

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study

Lancet Oncol

Kudo M, Abou-Alfa GK, Ren Z, Heo J, Lencioni R, Arai Y, Bouattour M, Gonzalez-Carmona MA, Guo Y, Xu AB, Alves GV, Dechaphunkul A, Ho GF, Lim YN, Hu H, Liu R, Gu S, Ostwal V, Manasirisuk W, Chiu CF, Tekumalla SH, Shroff M, Dave V, Rahma O, Erinjeri JP, Fan J, EMERALD-3 Investigators

doi: 10.1016/S1470-2045(26)00278-0

Related content

Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study

Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial

Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study

Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study